Actual aspects of vaginal progesterone use to prevent reproductive losses and optimize perinatal outcomes

Authors

  • Л. Г. Назаренко Kharkov Medical Academy of Postgraduate Education of the MoH of Ukraine, Kharkiv, Ukraine
  • Е. А. Бибик Hospital No. 6 of the Kharkiv City Council, Kharkiv, Ukraine https://orcid.org/0000-0003-0235-3961

DOI:

https://doi.org/10.18370/2309-4117.2019.50.22-28

Keywords:

miscarriage, spontaneous abortion, premature birth, micronized progesterone

Abstract

Miscarriage is a complex socio-medical problem, the relevance of which throughout the world is determined by the stable frequency of spontaneous abortions and premature births for half a century. Premature termination of pregnancy as a typical multifactorial disease regardless of the term has a universal pathogenetic mechanism of realization, which is progesterone deficiency. This justifies the need for subsidies with progesterone drugs for women at the real risk of miscarriage and preterm pregnancy.

The aim of the review is to summarize the information of relevant scientific publications with a high level of evidence on the effectiveness of progesterone drugs to prevent early spontaneous termination of pregnancy and an adverse perinatal outcome. To understand the features of micronized progesterone preparations that guarantee maximum effectiveness, to clarify the points of its application in connection with the risk of prematurity and perinatal outcome have been carried out studies in the world: PROMIS, TRISTAN-1, TRISTAN-2, OPPTIMUM, PRISM.

It is proved that the target groups for progesterone drugs are women with the threat of miscarriage in the early stages, patients with habitual miscarriage. Progesterone preparations (micronized progesterone) are aimed not only at prolonging pregnancy, but also at preventing late complications. To date, strong evidence has been obtained (PRISM, 2019) that vaginal micronized progesterone provides better results: live birth value in the general population of women with bloody discharge in the early period (4153 observations) is 3% more than placebo, best effect obtained women with a history of three or more miscarriages who have a 28% higher chance of a live baby (up to 34 weeks). A change in the system of views on assessing progestogen effectiveness in the treatment of miscarriage (its criterion is a live birth), the best prospects for viability, which is provided by proven safety and a positive effect on perinatal outcomes was noted.

Author Biographies

Л. Г. Назаренко, Kharkov Medical Academy of Postgraduate Education of the MoH of Ukraine, Kharkiv

MD, professor, head of the Department of Genetics, Obstetrics, Gynecology and Fetus Medicine

Е. А. Бибик, Hospital No. 6 of the Kharkiv City Council, Kharkiv

PhD, obstetrician-gynecologist of the Clinical Maternity

References

  1. Dubossarskа, Z.M., Dubossarskа, Y.A., Nagornyuk, V.T. “Predictors of preterm birth (literature review).” Obstetrics. Gynecology. Genetics 4.3 (2018): 5–10.
  2. Blencowe, H., Cousens, S., Oestergaard, M.Z., et al. “National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications.” The Lancet 379 (2012): 2162–72.
  3. Gami, G., Hakim, M., Nachum, Z., et al. “The impact of progesterone on the risk of preterm birth among women with second trimester bleeding. A multicenter, randomized, double-dlind, placebo controlled trial.” Am J Obstet Gynecol 218.1 (2018): 108.
  4. Nguyen, B.T., Chang, E.J., Bendikson, K.A. “Advanced paternal age and the risk of spontaneous abortion: an analysis of the combined 2011–2013 and 2013–2015 National Survey of Family Growth.” Am J Obstet Gynecol 221 (2019): 476.e1–7.
  5. Manuck, T.A., Rice, M.M., Bailit, J.L., et al. “Preterm neonatal morbidity and mortality by gestational age: a contemporary cohort.” Am J Obstet Gynecol 215 (2016): 103.e1–103.e14.
  6. Joseph, R.M., Korzeniewski, S.J., Allred, E.N., et al. “Extremely low gestational age and very low birthweight for gestational age are risk factors for autism spectrum disorder in a large cohort study of 10-yearold children born at 23-27 weeks’ gestation.” Am J Obstet Gynecol 216 (2017): 304.e1–304.e16.
  7. Radzinskyi, V.E., Orazmuradov, A.A., eds. Early terms pregnancy. From pregravid preparation to healthy gestation. Publishing house of the Media Bureau Status Presens (2018): 800 p.
  8. Radzinskyi, V.E. Obstetric aggression, v. 2.0. Moscow. Publishing House of the StatusPraesens journal (2017): 872 p.
  9. Nour, N.M. “Premature delivery and millennium development goal.” Rev Obstet Gynecol 5.2 (2013): 100–5.
  10. Senatorova, G.S., Riga, O.O., Ognev, V.A., Shevchenko, M.A. “Integral assessment of life quality and provision of medical care to reproductive age women on the model of Kharkiv region.” Pediatrics, obstetrics and gynecology 3 (2010): 98–101.
  11. Perfilova, I.N. “The role of placental mitochondria in the etiology and pathogenesis of pregnancy complications.” Obstetrics and gynecology 4 (2019): 5–11.
  12. Prokopenko, V.M., Pavlova, N.G., Arutyunyan, A.V. “Prooxidant and antioxidant systems in placental mitochondria during its dysfunction.” Journal of Obstetrics and Women's Diseases 5 (2010): 56–62.
  13. Baranov, V.S., ed. Genetic passport – the basis of individual and predictive medicine. St. Petersburg. Publishing House N-L (2009): 528 p.
  14. Shuhag, A., Sacchone, G., Berghella, V. “Vaginal progesterone for maintenance tocolysis: a meta-analysis of randomized trials.” Am J Obstet Gynecol 212.1 (2015): S137–S138.
  15. Nold, Ch., Maubert, M., Anton, L., et al. “Prevention of preterm birth by progestational agents: what are the molecular mechanisms?” Am J Obstet Gynecol 208 (2013): 223.e1–7.
  16. Tita, A., Rouse, D. “Progesterone for preterm birth prevention.” Am J Obstet Gynecol 10.1016 (2009): 219–24.
  17. Kumar, D., Springel, E., Moore, R.M., et al. “Progesterone inhibits in vitro fetal membrane weakening.” Am J Obstet Gynecol 213 (2015): 520.e1–520e9.
  18. DeFranco, E.A., DeArmond, Ch., Van Hook, J. “Progesterone administration for the prevention of preterm birth: effect on uterine blood flow dynamics.” Am J Obstet Gynecol 214.1 (2016): S293–94.
  19. O’Brien, J., Levis, D. “Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.” Am J Obstet Gynecol 214.1 (2016): 45–56.
  20. Pasricha, Sh., Bagga, R., Singla, P.B., et al. “Comparison of vaginal and intramuscular progesterone for preventing of preterm delivery in women with a prior preterm birth.” Am J Obstet Gynecol 216.1 (2017): S261–2.
  21. Campbell, S. “Prevention of spontaneous preterm birth: universal cervical length assessment and vaginal progesterone in women with a short cervix: time for action!” Am J Obstet Gynecol 218.2 (2018): 151–8.
  22. Frey, H.A., Finneran, M.M., Hade, E.M., et al. “A comparison of vaginal and intramuscular progesterone for prevention of recurrent preterm birth.” Am J Obstet Gynecol 220.1 (2019): S367.
  23. Boelig, R.C., Zuppa, A.F., Walter, K.K., Caritis, S. “Pharmacokinetics of vaginal progesterone in pregnancy.” Am J Obstet Gynecol 221.3 (2019): 263.e1–263.e7.
  24. Practice Committee of the American Association of Reproductive Medicine. “The clinical relevance of luteal phase deficiency: a committee opinion.” Fertil Steril 98.5 (2012):1112–7.
  25. Society for Maternal-Fetal Medicine Publications Committee. “The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth.” Am J Obstet Gynecol 216 (2017): B11–B13.
  26. Coomarasamy, A., et al. “A Randomized Trial of Progesterone in Women with Recurrent Miscarriages.” N Engl J Med 373 (2015): 2141–8.
  27. Haas, D.M., Ramsey, P.S. “Progestogen for preventing miscarriage.” Cochrane Database Syst Rev 10 (2013): CD003511.
  28. Ismail, A., et al. “Peri-conceptional progesterone treatment in women with unexplained recurrent miscarriage: a randomized double-blind placebo-controlled trial.” The Journal of Maternal-Fetal & Neonatal Medicine 31.3 (2018): 388–94. DOI: 10.1080/14767058.2017.1286315
  29. Savelyeva, G.M., Aksenenko, V.A., Andreeva, M.D., et al. “Therapy of habitual miscarriage with micronized progesterone (results of a multicenter study Tristan-1).” Obstetrics and Gynecology 11 (2017): 44–55.
  30. van Oppenraaij, R.H.F., et al. “Predicting adverse obstetric outcome after early pregnancy. Events and complications: a review.” Human Reproduction Update 15.4 (2009): 409–21.
  31. Ignatko, I.V., Strizhakov, A.N., Kuznetsov, A.S., et al. “The use of micronized progesterone in the prevention and treatment of miscarriage.” Obstetrics and Gynecology 2 (2019): 148–56.
  32. Savelyeva, G.M., Aksenenko, V.A., Andreeva, M.D., et al. “Outcomes of the second half of pregnancy in patients with a familiar history of miscarriage (results of a multicenter trial TRISTAN-2).” Obstetrics and Gynecology 8 (2018): 11–120.
  33. NICE Guideline No. 126. Ectopic pregnancy and miscarriage: diagnosis and initial management. Published date: April 2019.
  34. Coomarasamy, A., et al. “A Randomized Trial of Progesterone in Women with Early Pregnancy Bleeding.” N Engl J Med 380 (2019): 1815–24. DOI: 10.1056/NEJMoa1813730
  35. Ogasawara, M., et al. “Embryotic karyotype of abortuses in relation to the number of previous miscarriage.” Fertil Steril 73.2 (2000): 300–4.
  36. Koren, G., Gilboa, D., Kartz, P. “Fetal safety of dydrogesterone exposure in the first trimister of pregnancy.” Clinical Drug Investigation (2019). DOI: 10.1007/s40261-019-00862-w
  37. Zaqout, M., Aslem, E., Abuqamar, M., et al. “Association between oral intake of dydrogesterone during early pregnancy and congenital heart disease: a case-control study.” The Lancet 390.2 (2017): 8.
  38. Nelson, D.B., McIntire, D., McDonald, J., et al. “17-alfha Hydroxyprogesterona caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.” Am J Obstet Gynecol 216.6 (2017): 600.e1–600.e9.
  39. Conde-Agudelo, A., Romero, R. “Predictive accuracy of changes in transvaginal sonographic cervical length over time for preterm birth: a systematic review and metaanalysis.” Am J Obstet Gynecol 213 (2015): 789–801.
  40. Romero, R., Nicolaides, K., Conde-Agudelo, A., et al. “Vaginal progesterone decreases preterm birth = 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTIMUM study.” Ultrasound Obstet Gynecol 48 (2016): 308–17.
  41. Romero, R., Nicolaides, K., Conde-Agudelo, A., et al. “Vaginal progesterone in women an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data.” Am J Obstet Gynecol 206 (2012): 124.e1–19.
  42. Norman, J. “Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomized, double-blind trial.” The Lancet 387.10033 (2016): 2106–16.
  43. Romero, R., Conde-Agudelo, A., Da Fonseca, E., et al. “Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data.” Am J Obstet Gynecol 218.2 (2018): 161–180.
  44. Furcron, A., Romero, R., Plazyo, O., et al. “Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has anti-inflammatory effects at the murine maternal-fetal interface.” Am J Obstet Gynecol 213 (2015): 846.e1–19.
  45. Vink, J., Dahal, S., Li, H., et al. “Progesterone decreases human cervical smooth muscle cell contractility.” Am J Obstet Gynecol 220.1 (2019): S372.

Downloads

Published

2019-12-28

How to Cite

Назаренко, Л. Г., & Бибик, Е. А. (2019). Actual aspects of vaginal progesterone use to prevent reproductive losses and optimize perinatal outcomes. REPRODUCTIVE ENDOCRINOLOGY, (50), 22–28. https://doi.org/10.18370/2309-4117.2019.50.22-28

Issue

No. 50 (2019)

Section

Gynecology

License

Copyright (c) 2019 Л. Г. Назаренко, Е. А. Бибик

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.